
CervicalStim ↗
Prescription, non-invasive pulsed electromagnetic field device used alongside cervical fusion surgery in patients at high risk of non-fusion.
Historical PMA approvalPublic medical technology manufacturer serving spine surgery, bone healing and limb reconstruction, headquartered in Lewisville, Texas.
Orthofix Medical Inc. (NASDAQ: OFIX) is a medical technology manufacturer headquartered in Lewisville, Texas, with a history dating to 1980. Its portfolio spans spinal implants, biologics, therapeutic solutions, limb reconstruction and surgical navigation, serving surgeons, hospitals and patients.
The merger with SeaSpine became effective January 5, 2023, expanding the group across spinal implants, biologics and navigation. Its current commercial portfolio includes multiple product families and acquired brands. The regulatory snapshot links FDA decisions to current families while retaining discontinued and unresolved records separately.
Orthofix is an established commercial business: its website lists more than 1,600 employees worldwide. For the quarter ended June 30, 2026, the company reported $210.9 million in net sales and a $15.8 million net loss. These are dated company-reported figures, not an assessment of financial health.
Orthofix’s spine and orthopedic portfolio combines 510(k)-cleared families with original PMA lineages including CervicalStim (P030034), AccelStim (P210035), and PhysioStim/SpinalStim (P850007, counted once). SeaSpine and 7D histories retain the original applicants. The discontinued M6-C disc is excluded from current commercial counts while its authorization and recall history remain visible. The FDA decision/recall searches are completed for the named company and acquired applicants. Exact current-family assignment of some legacy/supplier records remains unestablished; those records are excluded from the snapshot. [298][297][295][483][479][481][456][469][4]
The matched FDA history contains 52 distinct recall events: 18 open, 34 terminated. 18 were initiated during the five years beginning October 20, 2021; older open events are also retained. Z-3226-2026 (2026-08-19; open, classified): The proximal thread depth of the spinal device is out of design specification. Z-2820-2026 (2026-07-02; open, classified): Demineralized bone matrix (DBM) in resorbable mesh indicated for use with autograft as a bone graft extender in the posterolateral spine and pelvis, were filled with approx. 4.5 cc DBM (fill for 45 11 mm configuration) instead of approx. 7.5 cc DBM (fill for 45 17.5 mm… Z-2729-2026 (2026-06-10; open, classified): Unilateral external fixation devices may be incorrectly labeled. Minirail M101 was labeled as M103, Minirail M103 was labeled as M101, and Minirail M122 was labeled as M111 [393][392][388][389][390][391]
Latest recorded source review: 2026-10-20.
Includes open events outside the mapped current portfolio; those events are excluded from the snapshot count.
| Recalled product / record | Initiated | Source |
|---|---|---|
| August 19, 2026 | [393][428] |
| July 2, 2026 | [392][428] |
| June 10, 2026 | [388][428] |
| May 28, 2026 | [387][428] |
| November 17, 2025 | [386][428] |
| November 3, 2025 | [380][383][385][428] |
| September 19, 2025 | [379][428] |
| August 6, 2025 | [377][428] |
| June 24, 2025 | [378][428] |
| February 20, 2025 | [375][428] |
| November 27, 2024 | [373][428] |
| November 27, 2024 | [374][428] |
| October 29, 2024 | [371][428] |
| September 24, 2024 | [376][428][513] |
| June 4, 2024 | [370][428] |
| May 17, 2024 | [368][428] |
| February 28, 2024 | [367][428] |
| February 15, 2024 | [366][428] |
Orthofix’s portfolio spans spine, limb reconstruction, bone growth therapies, biologics, navigation and bracing.

Prescription, non-invasive pulsed electromagnetic field device used alongside cervical fusion surgery in patients at high risk of non-fusion.
Historical PMA approval
Prescription ultrasound bone-growth stimulation system for indicated fracture-healing uses. Delivers low-intensity pulsed ultrasound to the treatment site.
Historical PMA approval
Implantable, powered intramedullary systems for limb lengthening and reconstruction. The family includes TAA, Trochanteric, and Transport and Lengthening configurations; indications vary by model.
510(k)-cleared configurations
Image-guided navigation platform using machine-vision registration for spine and cranial procedures. Authorized applications and instrument compatibility depend on the specific FDA labeling.
510(k)-cleared applicationsOrthofix announced the U.S. commercial launch of Fitbone Trochanteric in March 2026, adding another entry option to its limb-lengthening portfolio. This is a completed commercial milestone; the reviewed source does not establish a future FDA decision date for a separate development program. [436]
Orthofix reported net sales of $210.9 million and a net loss of $15.8 million for the quarter ended June 30, 2026. The report also describes the discontinuation of M6 product lines. [433]
FDA cleared K260146 for a Fitbone Transport and Lengthening line extension. The labeling specifies adult use. [481]
FDA reclassified non-invasive bone growth stimulators, including LOF devices, from Class III to Class II, effective May 18, 2026. This classification change is separate from the historical PMA decisions listed here. [514]
Orthofix eliminated the President, Global Spine Solutions role and aligned key spine leaders directly with the CEO, with an emphasis on commercial execution and 7D adoption. [431]
Orthofix announced the U.S. commercial launch of the Trochanteric configuration, complementing TAA and Transport and Lengthening systems. [436]
FDA records a recall affecting two specified Trochanteric nail units. The FDA posting followed in June 2025; status remains open at retrieval. [513]
The merger combined Orthofix and SeaSpine, adding complementary spine, biologics and navigation technologies. [429]
Accessed 10/29/2026